Extending clinical equipoise to phase 1 trials involving patients: Unresolved problems

Kennedy Institute of Ethics Journal

Volumn 20, Issue 1, 2010, Pages 75-98

  Anderson, James A ^a   Kimmelman, Jonathan ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; HUMAN; METHODOLOGY; PHASE 1 CLINICAL TRIAL; RESEARCH ETHICS; RESEARCH SUBJECT; RISK; SOCIAL PSYCHOLOGY; STANDARD; THERAPEUTIC EQUIPOISE;

CLINICAL TRIALS, PHASE I AS TOPIC; ETHICS, RESEARCH; HUMANS; RESEARCH SUBJECTS; RISK; SOCIAL VALUES; THERAPEUTIC EQUIPOISE;

EID: 77952844165     PISSN: 10546863     EISSN: 10863249     Source Type: Journal    
DOI: 10.1353/ken.0.0307     Document Type: Article

References (69)

1. AAMC. Association of American Medical Colleges. 2006. Promoting Translational and Clinical Science: The Critical Role of Medical Schools and Teaching Hospitals. Report of the AAMC's Task Force II on Clinical Research.
2. Agrawal, Manish, and Emanuel, Ezekiel J. 2003. Ethics of Phase 1 Oncology Studies: Reexamining the Arguments and Data. JAMA 290: 1075-1082
3. Anderson, James. 2006. The Ethics and Science of Placebo-Controlled Trials: Assay Sensitivity and the Duhem-Quine Thesis. Journal of Medicine and Philosophy 31: 65-81.
4. Annas, George, G. 1996. Questing for Grails: Duplicity, Betrayal and Self-Deception in Postmodern Medical Research. Journal of Contemporary Health Law and Policy 12: 297-324.
5. ASCO. American Society of Clinical Oncology. 1997. Critical Role of Phase I Clinical Trials in Cancer Treatment. Journal of Clinical Oncology 15: 853-859
6. Ashcroft, Richard. 1999. Equipoise, Knowledge, and Ethics in Clinical Research and Practice. Bioethics 13: 314-326
7. Babb, James S., and Rogatko, Andre. 2001. Patient Specific Dosing in a Cancer Phase I Clinical Trial. Statistics in Medicine 20: 2079-2090
8. Bebarta, Vik; Luyten, Dylan; and Heard, Kennon. 2003. Emergency Medicine Animal Research: Does Use of Randomization and Blinding Affect the Results? Academic Emergency Medicine 10: 684-687
9. Benatar, Michael. 2007. Lost in Translation: Treatment Trials in the SOD1 Mouse and in Human ALS. Neurobiology of Disease 26: 1-13.
10. Clark, Diana L.; Andrews, Paul A.; Smith, David D.; et al. 1999. Predictive Value of Preclinical Toxicology Studies for Platinum Anticancer Drugs. Clinical Cancer Research 5: 1161-1167
11. Committee on Strategies for Small-Number Participant Clinical Research Trials. 2001. Small Clinical Trials: Issues and Challenges, ed. Charles H. Evans, Jr., and Suzanne T. Ildstad. Washington, DC: National Academy Press.
12. Daugherty, Christopher K.; Ratain, Mark J.; Emanuel, Ezekiel J.; et al. 2008. Ethical, Scientific, and Regulatory Perspectives Regarding the Use of Placebos in Cancer Clinical Trials. Journal of Clinical Oncology 26: 1371-1378
13. Daugherty, Christopher K.; Ratain, Mark J.; Minami, Hironobu; et al. 1998. Study of Cohort-Specific Consent and Patient Control in Phase I Cancer Trials. Journal of Clinical Oncology 16: 2305-2312
14. Djulbegovic, Benjamin. 2007. Articulating and Responding to Uncertainties in Clinical Research. Journal of Medicine and Philosophy 32: 79-98.
15. Cantor, Alan; and Clarke, Mike. 2003. The Importance of the Preservation of the Ethical Principle of Equipoise in the Design of Clinical Trials: Relative Impact of the Methodological Quality Domains of the Treatment Effect in Randomized Controlled Trials. Accountability in Research 10: 301-315
16. Eisenhauer, Elizabeth A; Twelves, Christopher; and Buyse, Marc. 2006. Phase 1 Cancer Clinical Trials: A Practical Guide. Oxford: Oxford University Press.
17. Eisenhauer, E. A.; O'Dwyer, P. J.; Christian, M.; and Humphrey, J. S. 2000. Phase I Clinical Trial Design in Cancer Drug Development. Journal of Clinical Oncology 18: 684-692
18. Evans, Emily L., and London, Alex John. 2006. Equipoise and the Criteria for Reasonable Action. Journal of Law, Medicine and Ethics 34: 441-450
19. Fleming, Thomas R., and DeMets, David L. 1996. Surrogate End Points in Clinical Trials: Are We Being Misled? Annals of Internal Medicine 20: 637-648
20. FDA. Food and Drug Administration. 2004. Critical Path Report, Innovation or Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products.
21. 2006. FDA Guidance for Industry, Draft Guidance, INDs - Approaches to Complying with CGMP During Phase 1.
22. Freedman, Benjamin. 1987. Clinical Equipoise and the Ethics of Clinical Research. New England Journal of Medicine 317: 141-145
23. 1990. Placebo-Controlled Trials and the Logic of Clinical Purpose. IRB: Ethics and Human Research 12 (6): 1-6.
24. Freedman, Benjamin; Fuks, Abraham; and Weijer, Charles. 1992. Demarcating Research and Treatment: A Systematic Approach for the Analysis of the Ethics of Clinical Research. Clinical Research 40: 653-660
25. Fried, Charles. 1974. Medical Experimentation: Personal Integrity and Social Policy.Amsterdam: North Holland.
26. Gifford, Fred. 2007. Pulling the Plug on Clinical Equipoise: A Critique of Miller and Weijer. Kennedy Institute of Ethics Journal 17: 203-226
27. Gladstone David J.; Black, Sandra E.; and Hakim, Antoine M. 2002. Toward Wisdom from Failure: Lessons from Neuroprotective Stroke Trials and New Therapeutic Directions. Stroke 33: 2123-2136
28. Guyatt, Gordong H.; Haynes, R. Brain; Jaeschke, Roman Z.; et al. 2000. Users' Guides to the Medical Literature XXV. Evidence-Based Medicine: Principles for Applying the Users' Guides to Patient Care. JAMA 284: 1290-1296
29. Horstmann, Elizabeth; McCabe, Mary S.; Grochow, Loise; et al. 2005. Risks and Benefits of Phase 1 Oncology Trials, 1991 through 2002. New England Journal of Medicine 352: 895-904.
30. Joffe, Steven, and Miller, Franklin. 2006. Rethinking Risk-Benefit Assessment for Phase 1 Cancer Trials. Journal of Clinical Oncology 24: 2987-2990
31. Kimmelman, Jonathan. 2007. Ethics at Phase 0: Clarifying the Issues. Journal of Law, Medicine, and Ethics 35: 727-733
32. 2010. Gene Transfer and the Ethics of First-in-Human Research: Lost in Translation. Cambridge: Cambridge University Press.
33. London, Alex John; Ravine, Bernard; Ramsay, Tim; et al. 2009. Launching Invasive, First-in-Human Trials Against Parkinson's Disease: Ethical Considerations. Movement Disorders 24: 1893-1901
34. King, Nancy. 2000. Defining and Describing Benefit Appropriately in Clinical Trials. Journal of Law, Medicine & Ethics 28: 332-343
35. Koyfman, Shlomo A.; Agrawal, Manish; Garrett-Mayer, Elizabeth; et al. 2007. Risks and Benefits Associated with Novel Phase 1 Oncology Trial Designs. Cancer 110: 1115-1124
36. Le Tourneau, Christophe; Lee, J. Jack; and Siu, Lillian L. 2009. Dose Escalation Methods in Phase I Cancer Clinical Trials. Journal of the National Cancer Institute 101: 708-720
37. London, Alex John. 2005. Does Research Ethics Rest on a Mistake? The Common Good, Reasonable Risk and Social Justice. American Journal of Bioethics 5(1): 37-39.
38. 2006. Reasonable Risks in Clinical Research: A Critique and a Proposal for the Integrative Approach. Statistics in Medicine 25: 2869-2885
39. 2007. Clinical Equipoise: Foundational Requirement or Fundamental Error? In The Oxford Handbook of Bioethics, ed. Bonnie Steinbock, pp. 571-596 New York: Oxford University Press.
40. Lowenstein, Pedro R., and Castro, Maria G. 2009. Uncertainty in the Translation of Preclinical Experiments to Clinical Trials. Why Do Most Phase III Clinical Trials Fail? Current Gene Therapy 9: 368-374
41. MacLeod, Malcolm R.; O'Collins, Tori; Howells, David W.; and Donnan, Geoffrey A. 2004. Pooling of Animal Experimental Data Reveals Influence of Study Design and Publication Bias. Stroke 35: 1203-1208
42. Macleod, Malcolm R.; O'Collins, Tori; Horky, Laura L.; et al. 2005. Systematic Review and Meta-analysis of the Efficacy of FK506 in Experimental Stroke. Journal of Cerebral Blood Flow and Metabolism 25: 713-721 (Pubitemid 40705606)
43. Markman, Maurie. 2006. "Therapeutic Intent" in Phase 1 Oncology Trials: A Justifiable Objective. Archives of Internal Medicine 166: 1446-1448
44. Marquis, Don. 1983. Leaving Therapy to Chance. Hastings Center Report 13 (4): 40-47.
45. Meropol, Neal J. 2007. A Renewed Call for Equipoise. Journal of Clinical Oncology 25: 3392-3394
46. Miller, Franklin, and Brody, Howard. 2003. A Critique of Clinical Equipoise: Therapeutic Misconception in the Ethics of Clinical Trials. Hastings Center Report 33 (3): 19-28.
47. Miller, Franklin G., and Joffe, Steven. 2008. Benefit in Phase 1 Oncology Trials: Therapeutic Misconception or Reasonable Treatment Option? Clinical Trials 5: 617-623
48. Miller, Paul, and Weijer, Charles. 2003. Rehabilitating Equipoise. Kennedy Institute of Ethics Journal 13: 93-118.
49. 2006. Trust Based Obligations of the State and Physician Researchers to Patient-Subjects. Journal of Medical Ethics 32: 542-547
50. 2007. Equipoise and the Duty of Care in Clinical Research: A Philosophical Response to Our Critics. Journal of Medicine and Philosophy 32: 117-133
51. National Placebo Working Committee. 2005. Final Report of the National Placebo Working Committee on the Appropriate Use of Placebos in Clinical Trials in Canada. Ottawa, Canada: Canadian Institutes of Health Research. Available at http://www.cihr-irsc.gc.ca/e/25139.html, accessed 8 March 2010.
52. Newell, D. R.; Burtles, S. S.; Fox, B. W.; et al. 1999. Evaluation of Rodent-Only Toxicology for Early Clinical Trials with Novel Cancer Therapeutics. British Journal of Cancer 81: 760-768
53. Newell, D. R.; Silvester, J.; McDowell, C.; and Burtles, S. S. 2004. The Cancer Research UK Experience of Pre-Clinical Toxicology Studies to Support Early Clinical Trials with Novel Cancer Therapies. European Journal of Cancer 40: 899-906.
54. Paoletti, Xavier; Baron, Benoît; Schöffski, Patrick; et al. 2006. Using the Continual Reassessment Method: Lessons Learned from an EORTC Phase I Dose Finding Study. European Journal of Cancer 42: 1362-1368
55. Parulekar, Wendy R., and Eisenhauer, Elizabeth A. 2004. Phase I Trial Design For Solid Tumor Studies of Targeted, Non-Cytotoxic Agents: Theory and Practice. Journal of the National Cancer Institute 96: 990-997
56. Perel, Pablo; Roberts, Ian; Sena, Emily; et al. 2007. Comparison of Treatment Effects Between Animal Experiments and Clinical Trials: Systematic Review. BMJ 334: 197.
57. Philip, Maria; Benatar, Michael; Fisher, Marc; and Savitz, Sean I. 2009. Methodological Quality of Animal Studies of Neuroprotective Agents Currently in Phase II/III Acute Ischemic Stroke Trials. Stroke 40: 577-581
58. Piantadosi, Steven. 2005. Clinical Trials: A Methodologic Perspective. Second edition. Hoboken, NJ: John Wiley & Sons, Inc.
59. Roberts, Thomas G.; Goulart, Bernardo H.; Squitieri, Lee; et al. 2004. Trends in the Risks and Benefits to Patients with Cancer Participating in Phase 1 Clinical Trials. JAMA 292: 2130-2140
60. Ross, Lainie. 2006. Phase I Research and the Meaning of Direct Benefit. Journal of Pediatrics 149: S20-S24.
61. Saccardi, R.; Kozak, T.; Bocelli-Tyndall, C.; et al. 2006. Autologous Stem Cell Transplantation for Progressive Multiple Sclerosis: Update of the European Group for Blood and Marrow Transplantation Autoimmune Diseases Working Party Database. Multiple Sclerosis 12: 814-823
62. Simon, Richard; Freidlin, Boirs; Rubinstein, Larry; et al. 1997. Accelerated Titration Designs for Phase I Clinical Trials in Oncology. Journal of the National Cancer Institute 89: 1138-1147
63. Veatch, Robert. 2007. The Irrelevance of Equipoise. Journal of Medicine and Philosophy 32: 167-183
64. Weijer, Charles. 1999. Placebo-Controlled Trials in Schizophrenia: Are They Ethical? Are They Necessary? Schizophrenia Research 35: 211-218
65. -. 2003. The Ethics of Placebo-Controlled Trials. Journal of Bone and Mineral Research 18: 1150-1153
66. -, and Miller, Paul B. 2004. When Are Research Risks Reasonable in elation to Anticipated Benefits? Nature Medicine 10: 570-573
67. Weijer, Charles; Shapiro, Stanley H.; and Glass, Kathleen C. 2000. Clinical Equipoise and Not the Uncertainty Principle is the Moral Underpinning of the Randomized Controlled Trial. BMJ 321: 756-758
68. Wendler, David, and Miller, Franklin G. 2007. Assessing Research Risks Systematically: The Net Risks Test. Journal of Medical Ethics 33: 481-486
69. Zerhouni, Elias. 2003. The NIH Roadmap. Science 302: 63-72.